新辅助SHR-A1811联合或不联合吡咯替尼治疗局部晚期或早期HER2阳性乳腺癌女性的疗效与安全性:一项随机、开放标签、II期试验
该随机、开放标签、II期研究纳入265例II-III期HER2阳性乳腺癌患者,按1:1:1随机接受SHR-A1811单药、SHR-A1811联合吡咯替尼或PCbHP方案新辅助治疗24周。主要终点pCR率在三组间无显著差异:单药组63.2%、联合组62.5%、PCbHP组64.4%。≥3级治疗相关不良事件发生率分别为44.8%、71.6%和38.8%,未发生治疗相关死亡。
要点
- SHR-A1811单药、SHR-A1811联合吡咯替尼与PCbHP的pCR率分别为63.2%、62.5%和64.4%,三组间无显著差异。
- ≥3级治疗相关不良事件发生率:单药组44.8%、联合组71.6%、PCbHP组38.8%。
- 联合组中9.1%患者发生3级腹泻,单药组1例发生2级间质性肺病,无治疗相关死亡。
核心结论
- SHR-A1811在新辅助治疗中显示出稳健的抗肿瘤活性,安全性可耐受。
- 这是首个报告第三代HER2靶向抗体药物偶联物(ADC)在新辅助治疗HER2阳性乳腺癌中疗效与安全性的研究。
研究设计与样本
- 开放标签、随机、II期研究,纳入年龄≥18岁、II-III期HER2阳性乳腺癌患者。
- 患者按1:1:1随机分配接受SHR-A1811单药、SHR-A1811联合吡咯替尼或PCbHP方案新辅助治疗24周。
- 主要终点为病理完全缓解(pCR);安全性在至少接受一剂研究药物的患者中分析。
- 2022年12月27日至2024年2月11日期间,265例患者被随机分配至单药SHR-A1811组(n=87)、SHR-A1811联合吡咯替尼组(n=88)或PCbHP组(n=90)。
主要发现
- 基线特征均衡;约45%患者为激素受体(HR)阳性,70%患者为III期。
- pCR率:单药SHR-A1811组63.2%(HR阳性50%,HR阴性74.5%),SHR-A1811联合吡咯替尼组62.5%(HR阳性44.7%,HR阴性76%),PCbHP组64.4%(HR阳性54.1%,HR阴性71.7%),组间无显著差异。
- ≥3级治疗相关不良事件发生率:单药SHR-A1811组44.8%,SHR-A1811联合吡咯替尼组71.6%,PCbHP组38.8%。
- 单药SHR-A1811组1例患者发生2级间质性肺病;SHR-A1811联合吡咯替尼组9.1%患者发生3级腹泻;未发生治疗相关死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Standard neoadjuvant regimens for human epidermal growth factor receptor 2 (HER2)-positive breast cancer include trastuzumab and pertuzumab combined with chemotherapy, and the efficacy and safety of third-generation HER2-directed antibody-drug conjugate (ADC) remain to be elucidated. PATIENTS AND METHODS: This open-label, randomized, phase II study enrolled patients aged ≥18 years with stage II-III HER2-positive breast cancer. Patients were randomly assigned (1 : 1 : 1) to receive neoadjuvant treatment either with SHR-A1811 monotherapy, SHR-A1811 with pyrotinib, or nab-paclitaxel combined with carboplatin, trastuzumab, and pertuzumab (PCbHP) for 24 weeks. The primary endpoint was pathological complete response (pCR). Safety was analysed in patients who received at least one dose of study medication. RESULTS: Between 27 December 2022 and 11 February 2024, 265 patients were randomly allocated to neoadjuvant, mono-SHR-A1811 (n = 87), SHR-A1811 plus pyrotinib (n = 88), or PCbHP (n = 90). The baseline characteristics were well balanced; ∼45% of the patients were hormone receptor (HR) positive, and 70% of the patients were stage III. The pCR rate was 63.2% for mono-SHR-A1811 (50% for HR positive and 74.5% for HR negative), 62.5% for SHR-A1811 plus pyrotinib (44.7% for HR positive and 76% for HR negative), and 64.4% for PCbHP (54.1% for HR positive and 71.7% for HR negative), with no significant difference between the groups. Grade ≥3 treatment-related adverse events occurred in 44.8% of patients with mono-SHR-A1811, 71.6% with SHR-A1811 plus pyrotinib, and 38.8% with PCbHP. One patient experienced grade 2 interstitial lung disease in SHR-A1811, 9.1% of patients experienced grade 3 diarrhoea in SHR-A1811 plus pyrotinib, and no treatment-related deaths occurred. CONCLUSIONS: This is the first study to report the efficacy and safety of third-generation HER2-directed ADC in the neoadjuvant setting for HER2-positive breast cancer. SHR-A1811 showed robust activity, with a tolerable safety profile.
引用
- Li JJ, Wang ZH, Chen L, et al. Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial. Ann Oncol. 2025. PMID: 40049447. doi:10.1016/j.annonc.2025.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。